Currently ongoing clinical trials are investigating the use of CHK1 inhibitors (5) and WEE1 inhibitors (6) to enhance the cytotoxic effects of standard chemotherapies and improve AML patient responses. The gene discussed is CHEK1; the disease is acute myeloid leukemia.